DENVER, Colo., Nov 14, 2025 (247marketnews.com)- From autonomous drone systems to neuromuscular therapeutics, venue infrastructure, and antibody-based COVID prevention, traders are leaning into hard news, big guidance raises, and transformative corporate pivots.
Ondas Holdings (NASDAQ:ONDS) is one of today’s midday standouts after reporting a record-breaking Q3 2025, with revenue hitting $10.1 million, more than 6× year-over-year and 60% quarter-over-quarter.
The company now boasts a pro-forma cash balance of $840.4 million, one of the strongest in the autonomous robotics and defense-tech sector.
CEO Eric Brock emphasized sustained momentum at Ondas Autonomous Systems (OAS), citing demand strength for the Iron Drone Raider and Optimus System platforms. Brock said Ondas delivered a record quarter that was highlighted by sustained growth momentum amid a powerful demand cycle.
Key catalysts driving today’s surge:
- Record revenue and expanding backlog
- 2025 revenue target raised to at least $36M
- New 2026 preliminary target of $110M+
- Acquisitions of Sentrycs, Apeiro Motion, 4M Defense, and partnership with Rift Dynamics
- Expanding presence in Europe and Ukraine
- Strong progress at Ondas Networks as its dot16 platform is formalized as the upgrade path by the AAR’s Wireless Communications Committee
Brock concluded that Ondas is building a highly scalable platfolio, with clear visibility on significant revenue growth into 2026 and beyond, and investors are clearly buying in.
Scholar Rock (NASDAQ:SRRK) is trading higher midday after delivering a highly anticipated Q3 update and major FDA-related milestones tied to its groundbreaking SMA therapy, apitegromab.
The company announced a successful in-person Type A FDA meeting alongside Novo Nordisk’s Catalent Indiana team, confirming that the facility is on track to be reinspection-ready by year-end.
Key catalysts:
- BLA resubmission expected in 2026
- U.S. launch of apitegromab anticipated following approval
- Additional U.S. fill-finish facility accelerating timelines (commercial capacity secured for Q1 2026)
- Dosing underway in Phase 2 OPAL trial for infants <2 years old
- FDA clearance of SRK-439 IND, with dosing planned in Q4
- Cash runway into 2027
CEO David Hallal reaffirmed the company’s mission, noting its commitment to bringing apitegromab to children and adults living with SMA.
VENU (NYSE:VENU) reports after today’s close and traders are anticipating strong commentary on its live-entertainment infrastructure model.
What the market is watching:
- VENU’s model blends real estate, live entertainment, and hospitality, using build-own-earn and sale-leaseback strategies.
- Its $186M Colorado Springs appraisal (+46% over cost) and $14M parking asset sale ($6M profit) exemplify the model’s monetization power.
- The company is developing $5B+ worth of amphitheaters, with ~$1B already under construction.
- Long-term revenue potential includes $100M+ annual NNN leases and $2B in ticketing potential by 2030.
Although not a pure PPP play, VENU’s capital partnerships, asset monetization, and public-facing infrastructure make it PPP-adjacent, benefiting from the same macro tailwinds: real-asset inflation, scarce venue supply, and booming live-event demand.
Invivyd (NASDAQ:IVVD) is attracting buyers after reporting better-than-expected Q3 results and expanding its pipeline targeting next-gen COVID prevention.
Key Q3 highlights:
- PEMGARDA® revenue: $13.1M, up 41% YoY and 11% QoQ
- Cash exceeded $100M by October 2025
- Successful $57.5M public offering + $29.8M ATM usage
- FDA cleared IND for VYD2311, a vaccine-alternative preventative antibody
The pivotal REVOLUTION program includes two trials expected to begin around year-end 2025 with top-line data in mid-2026.
Shares of Cidara Therapeutics (NASDAQ:CDTX) are trending midday following overnight reports that Merck is nearing an acquisition potentially exceeding $3.3 billion.
Additional upside momentum comes from:
- Completion of Phase 3 trial enrollment
- Investor attention following a new 13D filing
- Heavy after-hours volume carrying over into today’s session
The market is pricing in a high-probability M&A scenario.
Formerly Leap Therapeutics, Cypherpunk Technologies (NASDAQ:CYPH) is one of today’s most-watched movers following its official rebrand and strategic shift into digital assets—while maintaining its oncology R&D through a dedicated subsidiary.
Recent catalysts:
- Closed a $58.88M private placement led by Winklevoss Capital
- Deployed $50M to build a Zcash-focused digital asset treasury
- Transitioning its cancer-therapy operations under a restored Leap Therapeutics subsidiary
- Trading under the new ticker CYPH as of November 13
CEO Douglas Onsi called the past month “transformative,” highlighting both the Zcash strategy and positive Phase 2 CRC data for sirexatamab.
MIDDAY OUTLOOK
With drones, therapeutics, AI-immune antibodies, live-event real assets, and digital-asset treasuries all moving simultaneously, today’s session is proving unusually catalyst-rich.
Expect heightened volatility into the close, especially with VENU (NYSE:VENU) reporting earnings after the bell.
For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/ or click here to read Cenorium’s full Venu analyst report on 247marketnews.com.
Contact [email protected] for Analyst Report coverage and other investor/public relations services.
About Venu Holding Corporation
Venu Holding Corporation (NYSE American: VENU) is redefining the live entertainment landscape through a national network of premium amphitheaters powered by its Luxe FireSuites model. With partnerships like AEG and Aramark, and an active development pipeline of over $5 billion (including $1 billion underway), Venu is building the next generation of destination venues, where investors, fans, and artists come together in a hospitality-first experience.
Through its innovative 40/40/20 financing model and integrated hospitality campuses, the company is building a national network of premium amphitheaters and entertainment destinations, targeting 40 venues by 2030. Its flagship Ford Amphitheater was nominated as Pollstar’s Best New Venue of 2024.
About 24/7 Market News
24/7 Market News (247) is a leading market news platform for public companies. As a pioneer in digital media, 247 is dedicated to the swift distribution of financial market news and information. 247 takes great pride in creating innovative public relations campaigns that help clients reach the target audience.
24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: Although 247 has not been compensated for this editorial, 247 has previously been compensated by MicroCap Strategies for press and editorial coverage of VENU and may be compensated again in the future. This editorial update is provided for informational purposes only and is intended for 247 readers and subscribers. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
CONTACT:
24/7 Market News
[email protected]
The post Defense Drones, SMA Breakthroughs, Live-Event Infrastructure, and COVID Prevention appeared first on 24/7 MarketNews.